Acute Myelogenous Leukemia (AML) Clinical Trials

A listing of Acute Myelogenous Leukemia (AML) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 531 clinical trials
Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

This is a non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-40279-01 in patients with Relapsed or Refractory AML.

refractory acute myeloid leukemia (aml)
  • 7 views
  • 27 May, 2021
  • 1 location
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single agent for the treatment of subjects with AML that is refractory to or relapsed after induction therapy

blast cells
hydroxyurea
neoadjuvant therapy
gilbert's syndrome
anthracyclines
  • 1 views
  • 02 Mar, 2021
  • 10 locations
Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

A prospective, single-arm, multicenter, exploratory study to evaluate the efficacy and safety of D-CLAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

cytarabine
idarubicin
decitabine
acute leukemia
refractory acute myeloid leukemia (aml)
  • 0 views
  • 26 Jan, 2021
  • 1 location
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

administered orally to participants 18 years of age with relapsed or refractory (R/R) acute myeloid leukemia (AML) or other myeloid neoplasms where approved therapies have failed or for whom known life

blast cells
blast crisis
refractory acute myeloid leukemia (aml)
  • 0 views
  • 24 Jul, 2021
  • 9 locations
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

This study will assess the safety and preliminary efficacy of escalating doses of SHR-1702 monotherapy in relapsed/refractory AML and intermediate-high risk MDS

  • 0 views
  • 27 Mar, 2021
  • 1 location
A Study of APG-115 Alone or in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

To determine the safety and tolerability of APG-115 combined with 5-azacitidine (5-AZA) in patients with relapsed/refractory AML

hydroxyurea
azacitidine
cell transplantation
ejection fraction
acute promyelocytic leukemia
  • 0 views
  • 29 Jul, 2021
  • 2 locations
IFN- to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

This study proposes a safe dosing regimen IFN- that is sufficient to stimulate IFNreceptors on malignant blasts in patients who developed relapsed acute myeloid leukemia (AML) or

  • 0 views
  • 22 Apr, 2021
  • 2 locations
T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Primary Objectives: This a pilot project to determine the feasibility of the preemptive CD8+ depleted T-cell donor lymphocyte infusion (DLI) in: - Reducing the incidence of graft versus host disease (GVHD) based on standard classification of acute and chronic GVHD - Improving hte disease remission rate in comparison with our …

leukemia
serum bilirubin level
high risk myelodysplastic syndrome
graft versus host disease
donor lymphocyte infusion
  • 35 views
  • 07 Nov, 2020
  • 1 location
PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years

Advances in the biological characterization of AML can now make a proper estimate of the risk of recurrence and likelihood of survival of different groups of patients according to the expression of different disease parameters. Karyotype, the molecular alterations affecting genes FLT3, NPM1 and CEBPA, minimal residual disease by flow …

cytarabine
flow cytometry
idarubicin
induction chemotherapy
minimal residual disease
  • 12 views
  • 29 Mar, 2021
  • 1 location
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

This phase I/2 trial studies the side effects and best dose of activated natural killer cells in treating patients with relapsed or refractory acute myeloid leukemia and myeloid dysplastic syndromes. Giving chemotherapy before a donor natural killer cell infusion helps stop the growth of cancer cells. It may also stop …

leukapheresis
fludarabine
cell transplantation
blast cells
acute promyelocytic leukemia
  • 79 views
  • 27 May, 2021
  • 1 location